{"filings":[{"id":68204,"accession_number":"0001493152-26-022721","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2026-05-13T20:10:20+00:00","items":["2.02","9.01"],"status":"ready","headline":"iMDx reports Q1 net loss $4.3M; signs first GALACTIC trial site, advances FDA submission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue ~$32K, gross profit $15K; net loss $4.3M ($0.12/share); non-GAAP net loss $9.6M ($0.28/share).","Signed first clinical trial agreement for GALACTIC registry with a top-10 U.S. kidney transplant center.","Non-GAAP operating expenses $4.4M including $5.9M non-cash gain; R&D down 15% sequentially.","Expect FDA marketing authorization for GraftAssureDx later 2026; productive FDA dialogue ongoing.","Small RUO orders from Switzerland and pending from Southeast Asia; first U.S. orders anticipated later this year."],"consensus_eps_estimate":-0.2667,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":32000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":68018,"accession_number":"0001493152-26-022708","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K/A","filed_at":"2026-05-13T20:05:17+00:00","items":["1.01","8.01"],"status":"ready","headline":"iMDx signs specimen collection agreement with Quest for GraftAssureCore test","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Entered Specimen Collection Agreement with Quest Diagnostics for services supporting GraftAssureCoreTM test.","GraftAssureCore is a blood test measuring donor-derived cell-free DNA (dd-cfDNA) via PCR platform.","Agreement covers specimen collection-related services to commercialize the test.","No financial terms or duration of the agreement disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94328,"accession_number":"0001493152-26-020461","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Insight Molecular Diagnostics corrects clerical error in bylaws exhibit","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Company filed corrected Third Amended and Restated Bylaws to replace erroneous exhibit 3.5.","Original exhibit inadvertently included shareholder voting provisions not part of Bylaws.","No other disclosures in the 10-K changed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106610,"accession_number":"0001493152-26-012915","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iMDx submits GraftAssureDx to FDA; Q4 revenue $1.1M, net loss $23.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Submitted GraftAssureDx kidney transplant test to FDA on March 25; expects 150-day review and authorization this year.","Full year 2025 revenue $4.1M (up from $1.9M); Q4 revenue $1.1M, net loss $23.0M ($0.72/share).","Adjusted Q4 net loss $8.7M ($0.27/share); R&D expenses rose 50% sequentially to $5.8M due to FDA submission.","Impaired oncology intangibles $14.6M ($11.7M DetermaCNI, $2.9M DetermaIO) to focus on transplant.","Appointed Dr. Nick Ioannou as VP Medical Affairs; completed $26M financing in February for heart expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106609,"accession_number":"0001493152-26-008169","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Insight Molecular Diagnostics enters specimen collection pact with Quest for GraftAssureCore test","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Quest Diagnostics dated Feb 20, 2026 for specimen collection services related to GraftAssureCore dd-cfDNA test.","Quest will provide services for the PCR-based blood test measuring donor-derived cell free DNA.","Parties also agree to negotiate additional rights to GraftAssure technology for a specified period.","Specific fees and financial terms not disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106608,"accession_number":"0001493152-26-006473","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"IMDX raises $26M in registered direct offering; funds heart transplant rejection test development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$26M from 4,525,976 shares/pre-funded warrants at $5.75/unit; net proceeds ~$24.5M.","Proceeds to expand GraftAssure product line into heart transplant rejection testing, beyond current kidney focus.","Bio-Rad Laboratories, significant shareholder, participated on same terms as other institutional investors.","Offering closed Feb 12, 2026; Lake Street Capital Markets acted as sole placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106607,"accession_number":"0001493152-26-006117","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Insight Molecular files 8-K with investor presentation; no specific financial details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Furnished investor slide deck under Item 7.01 for use in investor meetings.","No material financial or operational updates provided in the filing body.","Exhibit 99.1 content not available; presentation likely covers business overview and strategy.","Filing is routine Regulation FD disclosure; information is furnished, not filed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122938,"accession_number":"0001493152-25-021513","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"iMDx reports Q3 2025 net loss of $10.9M, advances toward FDA submission for GraftAssureDx by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $260k from lab services; gross margin 53.5%; net loss $10.9M ($0.34/sh); cash $20.2M.","On track to submit GraftAssureDx for FDA review by year-end; expect mid-2026 commercial launch.","19 transplant centers engaged with GraftAssure technology; goal of 20 by year-end; 11 clinical trial sites.","Operating expenses $11.2M include $3.4M non-cash contingent consideration change; R&D up 18% QoQ to $3.9M.","New VP Marketing Steven Tahmooressi hired; registry study of 5,000 patients planned; expanding into heart transplant testing."],"consensus_eps_estimate":-0.2139,"consensus_eps_actual":-0.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":2916000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122937,"accession_number":"0001493152-25-016685","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2025-10-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Insight Molecular grants stock options to four executives, amends CSO employment to indefinite term","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stock options: CEO Riggs 400k shares; CFO James and CSO Schütz 235k each; VP Liu 18k; exercise price $3.33.","Options vest over 3 years: 1/3 on first anniversary, then monthly over next 2 years, subject to continued service.","CSO Schütz's employment term amended from fixed 4-year to indefinite until termination; effective Sept 29, 2025.","Amendment removes references to 'Term Expiration' from severance provisions; all other terms unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139640,"accession_number":"0001493152-25-014240","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Insight Molecular Diagnostics raises CEO salary to $520K and CFO to $441K","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Joshua Riggs base salary increased from $420,000 to $520,000, effective Sept 15, 2025.","CFO Andrea James base salary increased from $341,250 to $441,250, effective same date.","Increases approved by Board and Compensation Committee on September 16, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139639,"accession_number":"0001641172-25-022974","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"IMDX Q2 rev $518K, net loss $9.7M; FDA on track for GraftAssureDx submission by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $518K vs $104K YoY; gross margin 67.6%, up from 62% in Q1.","Net loss $9.7M ($0.30/sh); non-GAAP operating loss $5.98M.","Cash $26.0M; quarterly cash spend ~$6M, in line with target.","FDA submission for GraftAssureDx on track for end-2025; marketing authorization expected mid-2026.","First RUO kit sale to Swiss hospital; Medicare boost to $2,753/test."],"consensus_eps_estimate":-0.2346,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":2656000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139638,"accession_number":"0001641172-25-017590","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shareholders approve all four proposals at Insight Molecular Diagnostics 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["73.46% quorum achieved; all four director nominees (Riggs, Arno, Last, Silverman) elected.","Ratified CBIZ CPAs P.C. as independent auditor for FY 2025 with 20,986,994 votes for.","Non-binding say-on-pay proposal approved with 18,063,639 votes for.","Amendment to 2018 Equity Incentive Plan approved; shares authorized increased by 1,500,000 to 3,800,000."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157221,"accession_number":"0001641172-25-015338","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.03","7.01","9.01"],"status":"ready","headline":"Oncocyte renames to Insight Molecular Diagnostics (iMDx), ticker changes to IMDX on June 18","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company changed name from Oncocyte Corp to Insight Molecular Diagnostics Inc. effective June 13, 2025.","Stock ticker changes from OCX to IMDX, effective before market open on June 18, 2025.","Principal executive office relocated from Irvine, CA to Nashville, TN; CLIA lab already in Nashville.","Product rebranding: VitaGraft Kidney (LDT) → GraftAssureCore, RUO kit → GraftAssureIQ, future IVD kit → GraftAssureDx.","CEO letter reports progress toward FDA submission of transplant rejection test kit; three top-10 US transplant centers engaged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157220,"accession_number":"0001641172-25-009681","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Oncocyte Q1 revenue $2.14M, gross margin 62%; transplant trial gets IRB approval","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 pharma services revenue $2.14M with 62% gross margin, up from 40% in Q4 2024.","Net loss $6.7M ($0.26 per share); non-GAAP loss from operations $5.0M.","Clinical trial design completed, central IRB approved; three top-10 US transplant centers expected to participate.","Ten leading transplant centers now using GraftAssure RUO kits; company plans to rename in Q2.","Cash balance $32.7M at quarter-end, including $28.7M net from February offering; Q1 operating cash use $5.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":2138000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157219,"accession_number":"0001641172-25-005288","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Oncocyte terminates Marcum as auditor, engages CBIZ CPAs for FY 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Marcum LLP effective April 11, 2025; engaged CBIZ CPAs P.C. on April 16, 2025 as auditor for FY 2025.","Change follows CBIZ CPAs' acquisition of Marcum's attest business effective November 1, 2024.","No disagreements or reportable events occurred during Marcum's tenure through April 11, 2025.","Marcum's reports for FY 2023 and 2024 were unqualified except for a going-concern note in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175574,"accession_number":"0001641172-25-000283","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Oncocyte Q4 revenue $1.5M, GAAP loss $33.5M; transplant test on track for 2026 FDA authorization","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 pharma-services revenue $1.5M; full-year $1.9M; gross margin 40%.","GAAP loss from continuing ops $33.5M ($1.93/sh); non-GAAP operating loss $4.4M.","Recorded $41.9M intangible impairment (DetermaCNI $35.1M, DetermaIO $6.8M) offset by $13.7M contingent consideration gain.","Cash $10.3M at year-end; raised $29.1M in Feb 2025 offering; Bio-Rad holds ~9.66% stake.","Targeting FDA submission for kitted transplant assay GraftAssureDx by end 2025; authorization expected 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175573,"accession_number":"0001493152-25-009684","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oncocyte promotes James Liu to VP Accounting, Controller, Treasurer; grants RSUs to executives","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Liu promoted to VP Accounting, Controller, Treasurer and Principal Accounting Officer, effective March 10, 2025; salary $225,000.","CEO Joshua Riggs annual salary raised to $420,000 from $400,000; CFO Andrea James to $341,250 from $325,000.","One-time RSU grants: CEO $600k (max 200k shares), CFO $360k (max 120k), CSO $360k (max 120k), vesting over 4 years.","CFO Andrea James receives $25,000 one-time bonus in cash or RSUs at her discretion.","James Liu also receives $60k in RSUs (3-year vest) and 10,000 options (4-year vest)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175572,"accession_number":"0001493152-25-005563","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","1.02","3.02","7.01","9.01"],"status":"ready","headline":"Oncocyte raises $29.1M equity; Bio-Rad invests; funds transplant assay to FDA clearance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $29.1M from registered direct ($7.4M) and PIPE ($21.7M) offerings at $2.05/share.","Five largest shareholders led round, including strategic partner Bio-Rad Laboratories (NYSE: BIO).","Proceeds expected to fully fund FDA IVD clearance and commercial launch of proprietary transplant assay.","Terminated at-the-market Sales Agreement with Needham; $1.8M previously sold under it."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175571,"accession_number":"0001493152-25-001389","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Oncocyte amends lease; terminates extension right, sets expiry Oct 2027, schedules $1.7M LC reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment entered Jan 2, 2025 with Induce Biologics and landlord Cushing Ventures.","Original lease expires Oct 31, 2027; all extension rights cancelled.","Letter of credit reduced by $60,714.29/month starting July 1, 2025 from $1.7M.","Reduction contingent on no continuing default; no assurance of reduction.","Reductions correspond to restricted cash on balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192525,"accession_number":"0001493152-24-044741","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Oncocyte reports Q3 loss of $13.5M; GraftAssure signed 2% US, 9% German transplant volumes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $115K from pharma services; loss from operations $13.5M ($0.98/sh); non-GAAP loss $5.6M.","Cash end Q3 $5.1M; raised $10.2M gross ($9.4M net) in Oct. private placement at $2.948/sh, 3.46M shares.","GraftAssure signed centers: ~9% German, ~2% US transplant volumes; on track for 20 centers by end of 2025.","FDA pre-sub (Q-sub) submitted for VitaGraft+ IVD; meeting scheduled early Dec.; six hospitals interested in clinical study.","Operating expenses (excl. non-cash) rose ~13% sequentially to $13.6M, driven by R&D and sales/marketing."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":395000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192524,"accession_number":"0001493152-24-041133","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Oncocyte shareholders approve 1.25M share increase to equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved Amended and Restated 2018 Equity Incentive Plan adding 1,250,000 shares, total pool now 2,300,000 shares.","Vote: 8,469,172 for, 110,188 against, 8,410 abstained; 64.21% of voting power represented at special meeting on Oct 11, 2024.","Amendments remove fungible share counting, eliminate share recycling restrictions, and remove one-year vesting minimum.","Plan authorizes delegation of award grants to executive officers under Board-established limits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192523,"accession_number":"0001493152-24-039269","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Oncocyte raises $10.2M in private placement, adds two major transplant centers as customers","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Private placement of 3.46M shares at $2.948/share raises ~$10.2M gross; includes participation from strategic partner Bio-Rad.","Proceeds for working capital and general corporate purposes; closing expected October 4, 2024.","Two leading transplant university hospitals in U.S. and Germany adopt GraftAssure research assay for graft damage monitoring.","Submitted Q-Sub to FDA for IVD version of dd-cfDNA test; FDA meeting scheduled for early December 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208988,"accession_number":"0001493152-24-030865","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Oncocyte enters $7.5M ATM with Needham, terminates prior $50M BTIG ATM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters Sales Agreement with Needham & Company for up to $7.5M of common stock at-the-market.","Terminates prior ATM agreement with BTIG, LLC dated June 11, 2021 for up to $50M.","Company may sell shares from time to time; Needham receives 3.0% commission on gross proceeds.","Net proceeds intended for working capital and general corporate purposes.","Placement shares registered under S-3 effective August 7, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208987,"accession_number":"0001493152-24-030771","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Oncocyte reports Q2 revenue $104K, loss $0.36/sh; launches GraftAssure at two centers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $104K from pharma services; operating expenses $4.7M; loss from ops $4.5M ($0.36/sh).","GraftAssure RUO assay used at two transplant centers in U.S. and Southeast Asia in July 2024.","Sales funnel represents centers covering ~25% of annual U.S. transplant volumes (11,000+ transplants).","Appointed Andrea James as CFO; she previously led IR at Axon and helped raise >$550M in equity.","Cash & equivalents $11.0M at June 30, up $3.7M sequentially; includes $1.7M restricted cash."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":280000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208986,"accession_number":"0001493152-24-027086","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Oncocyte gets Nasdaq notice of prior noncompliance and regained compliance after director death","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Director Alfred D. Kingsley died April 25, 2024, causing noncompliance with Nasdaq independent board and audit committee rules.","Effective July 1, 2024, director Andrew Arno was deemed independent and appointed to the audit committee, restoring compliance.","Nasdaq Staff confirmed compliance on July 8, 2024; no further action required.","The company had previously disclosed the independence determination in a Form 8-K filed July 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208985,"accession_number":"0001493152-24-026335","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-07-05T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"Oncocyte annual meeting elects directors, ratifies auditor; Board confirms Arno independence","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected four director nominees (Riggs, Arno, Last, Silverman) with ~7.98M votes each; quorum 81.5%.","Ratified Marcum LLP as auditor for FY2024: 10.8M for, 10.9k against, 11k abstain.","Approved non-binding say-on-pay proposal: 8.12M for, 20k against, 11k abstain.","Board determined Andrew Arno independent per Nasdaq rules as of July 1, 2024; Arno chairs Compensation, Last chairs Audit, Silverman chairs Nominating."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226831,"accession_number":"0001493152-24-024108","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Oncocyte appoints Andrea James as CFO, effective June 17, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andrea James appointed CFO; previously Chief Communications Officer at Axon Enterprise (AXON) and IR roles at Tesla.","Compensation: $325,000 base salary, 50% target bonus; option for 200,000 shares and 100,000 RSUs (subject to shareholder approval).","CEO Josh Riggs cites James' experience in capital raising and IR as company nears commercial launch.","James Liu remains Senior Director, Controller & Principal Accounting Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226830,"accession_number":"0001493152-24-022193","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oncocyte approves salary increases for CEO, interim CFO, and CSO effective May 20, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Joshua Riggs' base salary increased from $360,000 to $400,000.","Interim CFO/Principal Accounting Officer James Liu's salary raised from $200,000 to $207,000.","Chief Science Officer Ekkehard Schütz's salary rose from $351,525 to $378,025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226829,"accession_number":"0001493152-24-021144","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-05-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Oncocyte enters employment agreement with CSO; base salary $351,525","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Employment agreement with Chief Science Officer Ekkehard Schütz effective May 20, 2024; four-year term.","Base salary of $351,525.20; eligible for annual cash bonus of 50% of base salary.","Severance upon termination without cause or good reason includes 12 months base salary, pro-rata bonus, health coverage, and accelerated equity vesting.","Agreement replaces prior Managing Director Service Agreement with Chronix Biomedical GmbH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226828,"accession_number":"0001493152-24-019889","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Oncocyte Q1 revenue down 41% to $176K; operating loss $9.3M; Bio-Rad partnership","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net revenue $176K, down 41% YoY; operating loss $9.3M (incl. $3.3M contingent consideration loss) vs income $5.9M in Q1 2023.","Cash burn reduced to $3.9M in Q1; management targets average quarterly burn below $5M.","Announced global commercialization partnership with Bio-Rad; Bio-Rad also bought 8.99% stake via $15.8M equity private placement.","On track to ship RUO GraftAssure kits to initial customers in Asia, US, and EU during Q2 2024; IVD kit under development for FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":176000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226827,"accession_number":"0001493152-24-014380","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["1.01","2.02","7.01","3.02","8.01","9.01"],"status":"ready","headline":"Oncocyte raises $15.8M in private placement; FY2023 revenue $1.5M, ops loss $25.1M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of 5.1M shares + pre-funded warrants for 342k shares at $2.92/share; gross proceeds ~$15.8M.","Expected close April 15, 2024; $5M of proceeds to redeem Series A Preferred Stock; remainder for working capital.","FY2023 revenue $1.5M (+57%); operating loss $25.1M (+40%); cash burn Q4 2023 $4.4M, Q1 2024 est. $3.8M.","Bio-Rad partnership for transplant monitoring IP; GraftAssure product launch on track for Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226826,"accession_number":"0001493152-24-014355","cik":1642380,"company_name":"Insight Molecular Diagnostics Inc.","ticker":"IMDX","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Oncocyte partners with Bio-Rad for global transplant assay; Bio-Rad makes equity investment","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["10-year collaboration to develop/commercialize GraftAssure RUO and VitaGraft IVD assays on Bio-Rad's ddPCR platform.","GraftAssure RUO launch expected Q2 2024 at select US/EU transplant centers, broader rollout H2 2024.","Bio-Rad gets exclusive global distribution rights outside US/Germany; option for IVD rights upon FDA clearance with second equity investment.","Transplant monitoring market estimated over $1B with 157K annual transplants and 9.1% growth.","Bio-Rad makes initial equity investment in Oncocyte; specific amount not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":211823502.2028081,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}